7th International Mutant p53 Workshop 2016
 
 Preliminary Program


Wednesday 26 October, 2016

0800 - 0900

Registration

Session 1: Mutant p53 - from a discoverers perspective

0900 - 1000


Welcome
Ygal Haupt

Plenary Presentation
The evolution of tumors in Li Fraumeni Humans and Mice
Arnie Levine

1000 - 1030

Morning Tea

Session 2: P53 mutants as tools to define function
Session Chairs: Suzanne Cory & Jerry Adams

1030 - 1040

1040 - 1100

1100 - 1120


1120 - 1130


1130 - 1140

1140 - 1150


1150 - 1220


Welcome: Ricky Johnstone

A high throughput screen for novel genetic modifiers of TP53
David Thomas

Genotype-Phenotype correlations and cancer risk: lessons from TP53 mutations carriers
Pierre Hainaut

shRNA screens indicate that DNA repair is the process critical for p53-mediated tumour supression
Ana Janic

The mutant p53-ID4 complex controls VEGFA isoforms production by recruiting IncRNA MALAT1
Giulia Fontemaggi

Oncogenic activation of MIR205HG/miR-205 locus by p53 mutated protiens elicits cancer proliferation in Head and Neck squamous cell carcinoma
Silvia Agostino

Plenary Presentation
Leveraging p53 transactivation domain mutants to unravel p53 function
Laura Attardi

1230 - 1400

Lunch & Poster Session 1

Session 3: Regulation of Mutant p53 GOF
Session Chair: Giovanni Blandino

1400 - 1420


1420 - 1440


1440 - 1500


1500 - 1520

Targeting Mdm in mutant p53 expressing breast cancer
Ygal Haupt

Mutant p53 gains its new function via cell-cycle-regulated kinase and the action of c-Myc
Hua Lu

Influence of genotoxic drug-induced post-translational modifications on mutant p53 levels and function
David Meek

Mutant p53 and reprogramming of cancer cell proteome: mechanistic insights and therapeutic implications
Giannino Del Dal

1520 - 1600

Afternoon Tea

Session 4: Mutant p53 and family members
Session Chair: Kanaga Sabapathy

1600 - 1630


1630 - 1640



1640 - 1700


1700 - 1710


1710 - 1720



1720 - 1740

Plenary Presentation
The p53 family in cancer biology
Gerry Melino

Pharmacological re-activation of p53 protein family affects proliferation and migration of cancer cells with TP53 gene mutations
Joanna Zawacka-Pankau

Mutant p53 cooperates with p73 deficiency to promote tumorigenesis in vivo
Xinbin Chen

Identification of novel anti-metastatic targets of p73
Yatendra Satija

The N-terminal truncation of p53, delta40p53, represses estrogen-mediated induction of estrogen receptor alpha in breast cancer cells
Kelly Avery-Kiejda

Cell composition in mutant p53 isoforms define cell fate decision
Jean-Christophe Bourdon

1740 - 2100

Social Event - Welcome Reception


Thursday 27 October, 2016

0800 - 0830

Registration

Session 5: Mutant p53 in Human Cancer
Session Chair: Sue Haupt

0900 - 0930


0930 - 0950



0950 - 1010


1010 - 1030

Plenary Presentation
The Li-Fraumeni Syndrome Tumors: Can we find them? Can we cure them?
David Malkin

Mutation patterns in human cancers:comparative analyses of the IARC TP53 Database and genome-wide data
Magali Olivier

Germline mutant p53 in pediatric cancers
Gerard Zambetti

The importance of inherited p53 pathway mutations in cancer, other diseases and evolution
Gareth Bond

1030 - 1100

Morning Tea

Session 6: Mutant p53 in Human Cancer Continued
Session Chair: Marco Harold

1100 - 1120


1120 - 1140


1140 - 1200


1200 - 1210


1210 - 1225


Mutant p53 surfs into non-coding RNAs network
Giovanni Blandino

Circulating tumour DNA to monitor p53 in cancer
Sarah Jane Dawson

DNAJA1 controls the fate of misfolded mutant p53 via the mevalonate pathway
Tomoo Iwakuma

Genetic Modifiers of Radiation Response in LI-Fraumeni Syndrome
Katherine Sauberlie-Stewart

Mutant p53 synergizes with c-MYC over-expression and exerts a dominant negative effect that preferentially deregulates pathways for metabolism and DNA
Brandon Aubrey

1225 - 1400

Lunch & Poster Session 2

Session 7: Immunity
Session Chair: Shahneen Sandhu

1400 - 1420


1420 - 1440


1440 - 1455


1455 - 1505


1505 - 1525

Exomes and p53 Mutations
Curtis Harris

The impact of wild type and mutant p53 on the human immune system
Mike Resnick

Functional impact of p53 mutants on innate immune Toll-like receptor signalling in human cancer cells
Daniel Menendez

Mutant p53 promotes incorrect B cell differentiation and adverse outcome in DLBCL
Marina Kazantseva

A Delta133p53 isoform - like variant promotes inflammation which initiates an anti-tumour response
Antony Braithwaite

Session 8: Mutant p53 Drives growth, invasion & metastasis
Session Chair: Curtis Harris

1525 - 1545


1545 - 1555


1555 - 1605


1605 - 1615

TP53 missense mutations: a driver of metastasis in prostate cancer?
Chris Hovens

The Pro72Arg Polymorphism in cis with Mutant p53 has Significant Impact on Metastasis
Subhasree Basu

Gain-of-Function Mutant p53 Promotes the Oncogenic Potential of Head and Neck Squamous Cell Carcinoma Cell by Targeting Forkhead Transcription Factors FOXO3a and FOXM1
Ge Zhou

Mutant p53 promotes tumour growth by driving cancer cell engulfment activity
Hannah L Mackay

1615 - 1645

Afternoon Tea

Session 9: Novel Functions of p53 mutants & models
Session Chair: Mike Resnick

1645 - 1705


1705 - 1725


1725 - 1735



1735 - 1745


1745 - 1755


1755 - 1825

Oncogenic functions of mutant p53
Luis Martinez

Mutant p53 SNPs and cancer metabolism and metastasis
Maureen Murphy

A DNA damage tolerance pathway involving DNA polymerase iota and the tumor suppressor p53 regulates DNA replication fork progression
Stephanie Hampp

Elimination of spermatogonia with DNA damage via giant spermatogonial formaton and programmed cell death after loss of p53
Yuezhen Xue

Predicting mutant p53-dependent pancreatic cancer spread via intravital imaging in the E-cadherin biosensor mouse
David Herrmann

Plenary Presentation
Somatic versus germline p53 mutant models show differences in tumor evaluation
Guillermina (Gigi) Lozano

1830 - 2230

Social Event - Conference Dinner



Friday 28 October, 2016

0800 - 0830

Registration

Session 10: Mutant p53 therapies
Session Chair: Giannino Del Sal

0830 - 0900



0900 - 0920


0920 - 0940


0940 - 0955

Plenary Presentation
Targeting mutant p53 for therapy
Sir David Lane

Multiple approaches to target the different classes of mutant p53
Kanaga Sabapathy

Mechanisms of pharmacological restoration of mutant p53
Galina Selivanova

New routes to reactivating mutant p53
Chandra Verma 

1000 - 1030

Morning Tea

Session 11: Mutant p53 therapies continued 
Session Chair: Rick Pearson

1030 - 1050


1050 - 1110


1110 - 1125


1125 - 1135


1135 - 1145


1145 - 1155


1155 - 1215


Pharacological targeting of mutant p53 for treatment of cancer
Klas Wiman

Suppressing system xC- as a therapeutic strategy to target mutant-p53 cancers
Wayne Phillips

Genetic and pharmalogical ablation of mutant p53 inhibits CRC growth and invasiveness
Ramona Schulz

Developing an allele-specific cancer treatment strategy to target the various p53 mutants
Ifeoma Ubby

PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC)
Mikael von Euler

Targeting mutant p53 gain-of-function in head and necksquamous cell carcinoma with COTI-2, a novel 3rd generation thiosemicarbazone
Abdullah A Osman

Therapeutic activation of p53 following CDK4 inhibition in Melanoma
Grant McArthur


Session 12: Concluding Remarks 

1215 - 1300

Meeting Summary
Sir David Lane & Arnie Levine

Concluding Remarks
Ygal Haupt

1300

Lunch boxes to enjoy outdoors

* Program subject to change